Alzheimer's Disease and the Amyloid β Protein
暂无分享,去创建一个
[1] B. Sommer,et al. Neuron loss in APP transgenic mice , 1998, Nature.
[2] S. Tsuji,et al. Mis-sense mutation Val→Ile in exon 17 of amyloid precursor protein gene in Japanese familial Alzheimer's disease , 1991, The Lancet.
[3] A. Paetau,et al. A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1 , 1998, Nature Medicine.
[4] B. Hyman,et al. APPSW Transgenic Mice Develop Age‐related Aβ Deposits and Neuropil Abnormalities, but no Neuronal Loss in CA1 , 1997, Journal of neuropathology and experimental neurology.
[5] N Butters,et al. Clinical correlates of cortical and nucleus basalis pathology in Alzheimer dementia. , 1994, Archives of neurology.
[6] B. Sommer,et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[7] M. Pericak-Vance,et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[8] D. Selkoe,et al. Alzheimer's Disease--Genotypes, Phenotype, and Treatments , 1997, Science.
[9] B. Hyman,et al. Microglial response to amyloid plaques in APPsw transgenic mice. , 1998, The American journal of pathology.
[10] A. Alzheimer. Uber eine eigenartige Erkrankung der Hirnrinde , 1907 .
[11] M. Won,et al. Behavioral and Neuropathologic Changes Induced by Central Injection of Carboxyl‐Terminal Fragment of β‐Amyloid Precursor Protein in Mice , 1998, Journal of neurochemistry.
[12] S. Younkin,et al. Potentially amyloidogenic, carboxyl-terminal derivatives of the amyloid protein precursor. , 1992, Science.
[13] Davis Jn nd,et al. The 'amyloid cascade hypothesis' of AD: decoy or real McCoy? , 1997 .
[14] J. Hardy,et al. A new pathogenic mutation in the APP gene (I716V) increases the relative proportion of A beta 42(43). , 1997, Human molecular genetics.
[15] B. Winblad,et al. The significance of the Swedish APP670/671 mutation for the development of Alzheimer's disease amyloidosis , 1994, Neurochemistry International.
[16] M. Mattson,et al. beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[17] G. Cole,et al. Effects of injected Alzheimer beta-amyloid cores in rat brain. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[18] G. Getz,et al. Isoform-specific binding of apolipoprotein E to beta-amyloid. , 1994, The Journal of biological chemistry.
[19] K. Kawasaki,et al. Amyloid β Protein Potentiates Ca2+ Influx Through L‐Type Voltage‐Sensitive Ca2+ Channels: A Possible Involvement of Free Radicals , 1997, Journal of neurochemistry.
[20] J. Trojanowski,et al. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. , 1991, Science.
[21] D. Selkoe,et al. Oligomerization of endogenous and synthetic amyloid beta-protein at nanomolar levels in cell culture and stabilization of monomer by Congo red. , 1998, Biochemistry.
[22] G. Landreth,et al. Identification of Microglial Signal Transduction Pathways Mediating a Neurotoxic Response to Amyloidogenic Fragments of β-Amyloid and Prion Proteins , 1999, The Journal of Neuroscience.
[23] H. Braak,et al. Development of Alzheimer-related neurofibrillary changes in the neocortex inversely recapitulates cortical myelogenesis , 1996, Acta Neuropathologica.
[24] Bradley T. Hyman,et al. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease , 1992, Neurology.
[25] K Namekata,et al. Quantitation of amyloid beta-protein (A beta) in the cortex during aging and in Alzheimer's disease. , 1998, The American journal of pathology.
[26] P. Greengard,et al. Alzheimer Amyloid-β Peptide Forms Denaturant-Resistant Complex with Type ε3 but Not Type ε4 Isoform of Native Apolipoprotein E , 1996, Molecular medicine.
[27] Y. Sakaki,et al. Genomic organization of the human-amyloid beta-protein precursor gene. , 1990, Gene.
[28] B. Ghetti,et al. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. , 1991, Science.
[29] S. Younkin,et al. Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.
[30] M. Smith,et al. Evidence of oxidative stress and in vivo neurotoxicity of beta-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo. , 1998, The American journal of pathology.
[31] G. Schellenberg,et al. Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.
[32] John Hardy,et al. Amyloid, the presenilins and Alzheimer's disease , 1997, Trends in Neurosciences.
[33] D. Selkoe,et al. Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. , 1992, Science.
[34] J. Hardy,et al. Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene , 1991, Nature.
[35] R. Davidson,et al. Amyloid beta-peptide (AβP) potentiates a nimodipine-sensitive L-type barium conductance in N1E-115 neuroblastoma cells , 1994, Brain Research.
[36] D. Mann,et al. Presence of soluble amyloid β–peptide precedes amyloid plaque formation in Down's syndrome , 1996, Nature Medicine.
[37] K. Hsiao. Transgenic mice expressing Alzheimer amyloid precursor proteins , 1998, Experimental Gerontology.
[38] M. Goedert,et al. Tau protein pathology in neurodegenerative diseases , 1998, Trends in Neurosciences.
[39] L. Villa-komaroff,et al. Neurotoxicity of a fragment of the amyloid precursor associated with Alzheimer's disease. , 1989, Science.
[40] C. Behl,et al. Hydrogen peroxide mediates amyloid β protein toxicity , 1994, Cell.
[41] T. Morgan,et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[42] X. Chen,et al. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease , 1996, Nature.
[43] J. Price,et al. The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease , 1991, Neurobiology of Aging.
[44] J. Ulrich,et al. Alzheimer's Disease: A Description of the Structural Lesions , 1991, Brain pathology.
[45] T. Oltersdorf,et al. Cleavage of amyloid beta peptide during constitutive processing of its precursor. , 1990, Science.
[46] R. Martins,et al. Characterization of the Binding of Amyloid‐β Peptide to Cell Culture‐Derived Native Apolipoprotein E2, E3, and E4 Isoforms and to Isoforms from Human Plasma , 1997, Journal of neurochemistry.
[47] S. Younkin,et al. An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. , 1994, Science.
[48] Hugo Vanderstichele,et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein , 1998, Nature.
[49] M. Pericak-Vance,et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.
[50] M. Mattson,et al. A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[51] D. Selkoe,et al. Amyloid β-peptide is produced by cultured cells during normal metabolism , 1992, Nature.
[52] D. Selkoe,et al. Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor. , 1994, The Journal of biological chemistry.
[53] R. Mahley,et al. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.
[54] A. Roses. Apolipoprotein E Affects the Rate of Alzheimer Disease Expression: (β-Amyloid Burden Is a Secondary Consequence Dependent on APOE Genotype and Duration of Disease , 1994, Journal of neuropathology and experimental neurology.
[55] P. Lansbury,et al. Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? , 1993, Cell.
[56] J. Hardy,et al. Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.
[57] M. Mattson,et al. Cytochalasins Protect Hippocampal Neurons Against Amyloid β‐Peptide Toxicity: Evidence that Actin Depolymerization Suppresses Ca2+ Influx , 1995, Journal of neurochemistry.
[58] J. Hardy,et al. Increased Aβ42(43) from cell lines expressing presenilin 1 mutations , 1998, Annals of neurology.
[59] Brian J Cummings,et al. Image analysis of β-amyloid load in Alzheimer's disease and relation to dementia severity , 1995, The Lancet.
[60] A. Patel,et al. Presenilins and early-onset familial Alzheimer's disease. , 1997, Neuroreport.
[61] M. Emmerling,et al. Morphology and Toxicity of Aβ-(1-42) Dimer Derived from Neuritic and Vascular Amyloid Deposits of Alzheimer's Disease* , 1996, The Journal of Biological Chemistry.
[62] R. Terry. THE FINE STRUCTURE OF NEUROFIBRILLARY TANGLES IN ALZHEIMER'S DISEASE , 1963, Journal of neuropathology and experimental neurology.
[63] B. Hyman,et al. Alzheimer's mutation , 1991, Nature.
[64] M. Mattson,et al. Amyloid beta-peptide impairs ion-motive ATPase activities: evidence for a role in loss of neuronal Ca2+ homeostasis and cell death , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[65] G. Forloni,et al. Oxidative stress after acute and chronic application of β-amyloid fragment 25–35 in cortical cultures , 1996, Neuroscience Letters.
[66] L. Mucke,et al. Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein , 1995, Nature.
[67] C. Masters,et al. Strategic Thoughts on the Alzheimer’s Disease Amyloid Protein Precursor: The Way Forward , 1994 .
[68] M. Mattson,et al. Calcium-destabilizing and neurodegenerative effects of aggregated β-amyloid peptide are attenuated by basic FGF , 1993, Brain Research.
[69] M. Mattson,et al. β-Amyloid Peptide Free Radical Fragments Initiate Synaptosomal Lipoperoxidation in a Sequence-Specific Fashion: Implications to Alzheimer′s Disease , 1994 .
[70] J. Hardy,et al. Accelerated Alzheimer-type phenotype in transgenic mice carrying both mutant amyloid precursor protein and presenilin 1 transgenes , 1998, Nature Medicine.
[71] H. Brewer,et al. Amyloid-associated proteins α1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer β-protein into filaments , 1994, Nature.
[72] S. Paul,et al. Lack of apolipoprotein E dramatically reduces amyloid β-peptide deposition , 1997, Nature Genetics.
[73] A D Roses,et al. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[74] S. Younkin,et al. Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. , 1993, Science.
[75] P. Lansbury,et al. A detergent-insoluble membrance compartment contains Aβ in vivo , 1998, Nature Medicine.
[76] Carl W. Cotman,et al. In vitro aging of ß-amyloid protein causes peptide aggregation and neurotoxicity , 1991, Brain Research.
[77] Mark P. Mattson,et al. β-Amyloid precursor protein metabolites and loss of neuronal Ca2+ homeostasis in Alzheimer's disease , 1993, Trends in Neurosciences.
[78] D. Salmon,et al. Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.
[79] M. Beal,et al. An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[80] K. Grzeschik,et al. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor , 1987, Nature.
[81] M. Ball,et al. Water-soluble A(N-40, N-42) Oligomers in Normal and Alzheimer Disease Brains (*) , 1996, The Journal of Biological Chemistry.
[82] Xi Chen,et al. An intracellular protein that binds amyloid-β peptide and mediates neurotoxicity in Alzheimer's disease , 1997, Nature.
[83] R. Wetzel,et al. Aggregation state and neurotoxic properties of Alzheimer beta-amyloid peptide. , 1995, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.
[84] L. Mucke,et al. Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F β-Amyloid Precursor Protein and Alzheimer’s Disease , 1996, The Journal of Neuroscience.
[85] M. Pericak-Vance,et al. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[86] C. Masters,et al. Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[87] M. Tabaton,et al. Amyloid‐β Deposition in Alzheimer Transgenic Mice Is Associated with Oxidative Stress , 1998, Journal of neurochemistry.
[88] D. Small,et al. Role of Proteoglycans in Neural Development, Regeneration, and the Aging Brain , 1996, Journal of neurochemistry.
[89] R. Doms,et al. Detection of a Novel Intraneuronal Pool of Insoluble Amyloid β Protein that Accumulates with Time in Culture , 1998, The Journal of cell biology.